EquitySector - HealthcareVery High Risk
Regular
NAV (28-Aug-25)
Returns (Since Inception)
Fund Size
₹1,339 Cr
Expense Ratio
2.10%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.33%
+3.06% (Cat Avg.)
3 Years
+23.67%
+23.47% (Cat Avg.)
5 Years
+18.33%
+18.47% (Cat Avg.)
Since Inception
+12.22%
— (Cat Avg.)
Equity | ₹1,255.76 Cr | 93.78% |
Others | ₹83.23 Cr | 6.22% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹146.17 Cr | 10.92% |
Cipla Ltd | Equity | ₹88.6 Cr | 6.62% |
Apollo Hospitals Enterprise Ltd | Equity | ₹69.6 Cr | 5.20% |
Lupin Ltd | Equity | ₹63.83 Cr | 4.77% |
A) Repo | Cash - Repurchase Agreement | ₹61.1 Cr | 4.56% |
HealthCare Global Enterprises Ltd | Equity | ₹58.63 Cr | 4.38% |
Torrent Pharmaceuticals Ltd | Equity | ₹57.89 Cr | 4.32% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹57.89 Cr | 4.32% |
Fortis Healthcare Ltd | Equity | ₹53.56 Cr | 4.00% |
Alkem Laboratories Ltd | Equity | ₹53.55 Cr | 4.00% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹50.83 Cr | 3.80% |
Wockhardt Ltd | Equity | ₹45.83 Cr | 3.42% |
Divi's Laboratories Ltd | Equity | ₹40.98 Cr | 3.06% |
Dr. Lal PathLabs Ltd | Equity | ₹38.48 Cr | 2.87% |
Metropolis Healthcare Ltd | Equity | ₹36.24 Cr | 2.71% |
Ajanta Pharma Ltd | Equity | ₹35.7 Cr | 2.67% |
Ipca Laboratories Ltd | Equity | ₹34.63 Cr | 2.59% |
Aurobindo Pharma Ltd | Equity | ₹29.84 Cr | 2.23% |
Mankind Pharma Ltd | Equity | ₹28.72 Cr | 2.15% |
Rainbow Childrens Medicare Ltd | Equity | ₹28.17 Cr | 2.10% |
FDC Ltd | Equity | ₹27.37 Cr | 2.04% |
Dr Reddy's Laboratories Ltd | Equity | ₹26.87 Cr | 2.01% |
Dr Agarwal’s Health Care Ltd | Equity | ₹25.12 Cr | 1.88% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹24.6 Cr | 1.84% |
Cash / Net Current Asset | Cash | ₹22.13 Cr | 1.65% |
Niva Bupa Health Insurance Co Ltd | Equity | ₹21.89 Cr | 1.63% |
Syngene International Ltd | Equity | ₹21.13 Cr | 1.58% |
Indoco Remedies Ltd | Equity | ₹13.62 Cr | 1.02% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹13.36 Cr | 1.00% |
Zydus Lifesciences Ltd | Equity | ₹13.31 Cr | 0.99% |
Medi Assist Healthcare Services Ltd | Equity | ₹13.05 Cr | 0.97% |
Medplus Health Services Ltd | Equity | ₹11.06 Cr | 0.83% |
Hikal Ltd | Equity | ₹10.22 Cr | 0.76% |
Jupiter Life Line Hospitals Ltd | Equity | ₹7.11 Cr | 0.53% |
Acutaas Chemicals Ltd | Equity | ₹6.11 Cr | 0.46% |
Krsnaa Diagnostics Ltd | Equity | ₹1.2 Cr | 0.09% |
Laxmi Dental Ltd | Equity | ₹0.61 Cr | 0.05% |
Large Cap Stocks
43.83%
Mid Cap Stocks
15.48%
Small Cap Stocks
34.48%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,227.77 Cr | 91.69% |
Financial Services | ₹21.89 Cr | 1.63% |
Basic Materials | ₹6.11 Cr | 0.46% |
Standard Deviation
This fund
15.78%
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
1.05
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.10% | Exit Load No Charges | Fund Size ₹1,339 Cr | Age 9 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹2,11,753 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (28-Aug-25)
Returns (Since Inception)
Fund Size
₹1,339 Cr
Expense Ratio
2.10%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.33%
+3.06% (Cat Avg.)
3 Years
+23.67%
+23.47% (Cat Avg.)
5 Years
+18.33%
+18.47% (Cat Avg.)
Since Inception
+12.22%
— (Cat Avg.)
Equity | ₹1,255.76 Cr | 93.78% |
Others | ₹83.23 Cr | 6.22% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹146.17 Cr | 10.92% |
Cipla Ltd | Equity | ₹88.6 Cr | 6.62% |
Apollo Hospitals Enterprise Ltd | Equity | ₹69.6 Cr | 5.20% |
Lupin Ltd | Equity | ₹63.83 Cr | 4.77% |
A) Repo | Cash - Repurchase Agreement | ₹61.1 Cr | 4.56% |
HealthCare Global Enterprises Ltd | Equity | ₹58.63 Cr | 4.38% |
Torrent Pharmaceuticals Ltd | Equity | ₹57.89 Cr | 4.32% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹57.89 Cr | 4.32% |
Fortis Healthcare Ltd | Equity | ₹53.56 Cr | 4.00% |
Alkem Laboratories Ltd | Equity | ₹53.55 Cr | 4.00% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹50.83 Cr | 3.80% |
Wockhardt Ltd | Equity | ₹45.83 Cr | 3.42% |
Divi's Laboratories Ltd | Equity | ₹40.98 Cr | 3.06% |
Dr. Lal PathLabs Ltd | Equity | ₹38.48 Cr | 2.87% |
Metropolis Healthcare Ltd | Equity | ₹36.24 Cr | 2.71% |
Ajanta Pharma Ltd | Equity | ₹35.7 Cr | 2.67% |
Ipca Laboratories Ltd | Equity | ₹34.63 Cr | 2.59% |
Aurobindo Pharma Ltd | Equity | ₹29.84 Cr | 2.23% |
Mankind Pharma Ltd | Equity | ₹28.72 Cr | 2.15% |
Rainbow Childrens Medicare Ltd | Equity | ₹28.17 Cr | 2.10% |
FDC Ltd | Equity | ₹27.37 Cr | 2.04% |
Dr Reddy's Laboratories Ltd | Equity | ₹26.87 Cr | 2.01% |
Dr Agarwal’s Health Care Ltd | Equity | ₹25.12 Cr | 1.88% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹24.6 Cr | 1.84% |
Cash / Net Current Asset | Cash | ₹22.13 Cr | 1.65% |
Niva Bupa Health Insurance Co Ltd | Equity | ₹21.89 Cr | 1.63% |
Syngene International Ltd | Equity | ₹21.13 Cr | 1.58% |
Indoco Remedies Ltd | Equity | ₹13.62 Cr | 1.02% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹13.36 Cr | 1.00% |
Zydus Lifesciences Ltd | Equity | ₹13.31 Cr | 0.99% |
Medi Assist Healthcare Services Ltd | Equity | ₹13.05 Cr | 0.97% |
Medplus Health Services Ltd | Equity | ₹11.06 Cr | 0.83% |
Hikal Ltd | Equity | ₹10.22 Cr | 0.76% |
Jupiter Life Line Hospitals Ltd | Equity | ₹7.11 Cr | 0.53% |
Acutaas Chemicals Ltd | Equity | ₹6.11 Cr | 0.46% |
Krsnaa Diagnostics Ltd | Equity | ₹1.2 Cr | 0.09% |
Laxmi Dental Ltd | Equity | ₹0.61 Cr | 0.05% |
Large Cap Stocks
43.83%
Mid Cap Stocks
15.48%
Small Cap Stocks
34.48%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,227.77 Cr | 91.69% |
Financial Services | ₹21.89 Cr | 1.63% |
Basic Materials | ₹6.11 Cr | 0.46% |
Standard Deviation
This fund
15.78%
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
1.05
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.10% | Exit Load No Charges | Fund Size ₹1,339 Cr | Age 9 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹2,11,753 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments